Korean Biotech firm, LegoChem Biosciences has been at the forefront of Antibody-Drug Conjugate (ADC) development, securing partnerships, significant investment, and licensing deals with numerous big names in the industry. The company has raised substantial capital ($411M) from confectionery giant, Orion, who in turn has bought a majority stake securing stronger finances for LegoChem. The firm has also partnered with Samsung Biologics, in efforts to accelerate ADC production. Further bolstering its portfolio, LegoChem signed a historic $1.72b deal with J&J's Janssen and another $1.7 billion ADC deal with Janssen. These partnership agreements solidify the company's likelihood for further ADC development and production. Issuance of FDA approval for Phase 1,2 trials of LCB84, a Trop2-Targeted ADC, indicates progress in preclinical development. The company's in-house research team found new autotaxin inhibitors to further their innovative exploration. Despite currently being unprofitable, LegoChem provided a remarkable 92% return to shareholders over 5 years. However, it suffered a setback after a legal defeat to Lego where it considered changing its name.
Legochem News Analytics from Mon, 13 Feb 2017 08:00:00 GMT to Wed, 08 May 2024 23:29:46 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -5
